These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 21655094)

  • 1. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
    PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
    Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells.
    Sakuma Y; Matsukuma S; Nakamura Y; Yoshihara M; Koizume S; Sekiguchi H; Saito H; Nakayama H; Kameda Y; Yokose T; Oguni S; Niki T; Miyagi Y
    Lab Invest; 2013 Oct; 93(10):1137-46. PubMed ID: 23938604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
    Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
    J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
    Chang X; Izumchenko E; Solis LM; Kim MS; Chatterjee A; Ling S; Monitto CL; Harari PM; Hidalgo M; Goodman SN; Wistuba II; Bedi A; Sidransky D
    PLoS One; 2013; 8(7):e68966. PubMed ID: 23935914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
    Fung C; Chen X; Grandis JR; Duvvuri U
    Cancer Biol Ther; 2012 Dec; 13(14):1417-24. PubMed ID: 22954701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
    Bokobza SM; Jiang Y; Weber AM; Devery AM; Ryan AJ
    Oncotarget; 2014 Jul; 5(13):4765-78. PubMed ID: 24946858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
    Tabara K; Kanda R; Sonoda K; Kubo T; Murakami Y; Kawahara A; Azuma K; Abe H; Kage M; Yoshinaga A; Tahira T; Hayashi K; Arao T; Nishio K; Rosell R; Kuwano M; Ono M
    PLoS One; 2012; 7(7):e41017. PubMed ID: 22815900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
    Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
    PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
    Cao Q; You X; Xu L; Wang L; Chen Y
    Autophagy; 2020 Jul; 16(7):1236-1247. PubMed ID: 31448672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
    J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
    Choi DY; You S; Jung JH; Lee JC; Rho JK; Lee KY; Freeman MR; Kim KP; Kim J
    Proteomics; 2014 Aug; 14(16):1845-56. PubMed ID: 24946052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
    Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
    Holland WS; Chinn DC; Lara PN; Gandara DR; Mack PC
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):615-26. PubMed ID: 25323938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.